{"id":"W4308769923","doi":"10.1136/ard-2022-223356","title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1788,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"Medac; National Institute for Health and Care Research; European League Against Rheumatism; Biogen; Gilead Sciences; Sanofi; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Antirheumatic drugs; Rheumatoid arthritis; Antirheumatic Agents; Arthritis; Hydroxychloroquine; Disease; Biological drugs; Intensive care medicine; Immunology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}